- Home
- ERAS vs MTRX Comparison
ERAS vs MTRX Comparison
Compare ERAS & MTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- MTRX
- Stock Information
- Founded
- ERAS 2018
- MTRX 1984
- Country
- ERAS United States
- MTRX United States
- Employees
- ERAS N/A
- MTRX N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- MTRX Engineering & Construction
- Sector
- ERAS Health Care
- MTRX Consumer Discretionary
- Exchange
- ERAS Nasdaq
- MTRX Nasdaq
- Market Cap
- ERAS 348.4M
- MTRX 327.8M
- IPO Year
- ERAS 2021
- MTRX 1990
- Fundamental
- Price
- ERAS $1.36
- MTRX $12.25
- Analyst Decision
- ERAS Strong Buy
- MTRX Strong Buy
- Analyst Count
- ERAS 6
- MTRX 1
- Target Price
- ERAS $4.83
- MTRX $20.00
- AVG Volume (30 Days)
- ERAS 1.5M
- MTRX 184.7K
- Earning Date
- ERAS 05-13-2025
- MTRX 05-07-2025
- Dividend Yield
- ERAS N/A
- MTRX N/A
- EPS Growth
- ERAS N/A
- MTRX N/A
- EPS
- ERAS N/A
- MTRX N/A
- Revenue
- ERAS N/A
- MTRX $742,408,000.00
- Revenue This Year
- ERAS N/A
- MTRX $9.98
- Revenue Next Year
- ERAS N/A
- MTRX $20.42
- P/E Ratio
- ERAS N/A
- MTRX N/A
- Revenue Growth
- ERAS N/A
- MTRX N/A
- 52 Week Low
- ERAS $1.01
- MTRX $8.61
- 52 Week High
- ERAS $3.45
- MTRX $15.75
- Technical
- Relative Strength Index (RSI)
- ERAS 54.43
- MTRX 47.99
- Support Level
- ERAS $1.06
- MTRX $12.05
- Resistance Level
- ERAS $1.47
- MTRX $12.58
- Average True Range (ATR)
- ERAS 0.14
- MTRX 0.42
- MACD
- ERAS 0.02
- MTRX -0.08
- Stochastic Oscillator
- ERAS 70.65
- MTRX 24.27
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.